海洋大藻多作为神经退行性疾病中的潜在神经保护性抗氧化剂
Silvia Lomartire1, Ana M M Gonçalves1,2
1University of Coimbra, MARE-Marine and Environmental Sciences Centre/ARNET-Aquatic Research Network, Department of Life Sciences, Calçada Martim de Freitas, 3000-456 Coimbra, Portugal.
Marine drugs
|May 26, 2023
概括
来自海藻的海洋聚醇显示出强大的抗氧化和神经保护作用. 这些天然化合物可能会减缓神经退行性疾病的进展,减少神经元损失,改善患者的生活质量.
科学领域:
- 海洋生物学 海洋生物学
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
背景情况:
- 多,具有抗氧化特性的天然化合物,正在获得治疗应用的兴趣.
- 海洋大藻,特别是棕藻,是富含多的丰富来源,具有显著的抗氧化活性.
- 神经退行性疾病的特征是氧化应激和神经元细胞损失.
研究的目的:
- 审查目前关于海藻衍生的多的神经保护性抗氧化活性的证据.
- 探索海洋多在治疗神经退行性疾病的药物开发中的潜力.
- 讨论海洋多的抗氧化作用背后的机制.
主要方法:
- 在体外和体内研究研究研究海藻多提取物.
- 对抗氧化活性和神经保护机制的分析.
- 对最近的科学文献进行审查.
主要成果:
- 海洋多具有显著的抗氧化特性.
- 与红色和绿色藻类相比,棕色藻类产生的多具有更高的抗氧化活性.
- 有证据表明,海洋多可以减轻氧化应激,并保护神经元细胞.
结论:
- 海藻衍生的多具有显著的神经保护性抗氧化剂潜力.
- 这些化合物可能提供一种治疗策略,以延缓神经退行性疾病中神经元细胞损失.
- 海洋多代表了未来神经学药物开发的一个有希望的途径.
更多相关视频
相关概念视频
Alzheimer's Disease: Treatment
226
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
226
Red Algae
68
Red algae, also known as rhodophytes, are primarily found in marine environments, though some species inhabit freshwater and terrestrial ecosystems. These organisms exist in both unicellular and multicellular forms, with some multicellular varieties reaching macroscopic sizes.As phototrophic organisms, red algae contain chlorophyll a; however, their chloroplasts lack chlorophyll b. Instead, they possess phycobiliproteins, which serve as major light-harvesting pigments, similar to those found in...
68
Alzheimer's Disease: Overview
541
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
541


